Useful knee care starts with strength and motion

Simple care works when you keep doing it

Short walks can keep your knee loose. They'll also keep your legs working. Cut long periods of standing during a flare.

A brace may steady some knees.

Pain-relief cream or gel may also help. Ask your doctor whether it fits your medicines. If extra weight adds strain, a small loss may ease soreness. You can note how your knee feels after exercise. It'll show whether soreness settles by morning.

Some treatments ease soreness for a short time

A steroid shot may ease soreness for several weeks. It won't usually give lasting relief. Repeated shots can carry added risks.

Research on blood-based care isn't settled.

Some people say their knees hurt less. Those reports are anecdotal, meaning they're personal accounts rather than a fair test. Get the treatment name and clinician's name in writing.

Knee replacement alternatives can delay surgery

Exercise, a brace, weight loss, and short-term care may buy time. They won't rebuild worn cartilage. They may still help you do more.

Strong rest pain can change the choice.

Lost sleep and poor walking also matter. Ask what surgery could improve and what recovery requires. At Chandler, QC Kinetix medical providers offer orthobiologics, meaning blood-based treatments such as PRP: they draw and spin your blood, then place the prepared part in your knee.

Sources

1. The 2019 ACR/Arthritis Foundation guideline makes STRONG recommendations for exercise, weight loss in people with overweight or obesity, self-efficacy and self-management programs, tai chi, cane use, tibiofemoral bracing, topical NSAIDs, oral NSAIDs and intra-articular glucocorticoid injections in knee OA; radiofrequency ablation for knee OA is only a conditional recommendation.

   Kolasinski SL, et al. — 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee.. Arthritis & Rheumatology, 2020. DOI: 10.1002/art.41142.

2. OARSI 2019 designates arthritis education plus structured land-based exercise (with or without dietary weight management) as CORE treatments for knee OA; topical NSAIDs are strongly recommended (Level 1A); oral and transdermal opioids are strongly NOT recommended (Level 5).

   Bannuru RR, et al. — OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis.. Osteoarthritis and Cartilage, 2019. DOI: 10.1016/j.joca.2019.06.011.

3. High-quality evidence from 44 trials (3,537 participants) shows land-based exercise reduced knee OA pain by an equivalent of 12 points on a 0-100 scale (SMD -0.49) immediately after treatment, with moderate-quality evidence for a ~10-point function gain; the effect attenuated but persisted at 2-6 months (SMD -0.24). No serious adverse events were reported in any included trial.

   Fransen M, McConnell S, Harmer AR, Van der Esch M, Simic M, Bennell KL. — Exercise for osteoarthritis of the knee.. Cochrane Database of Systematic Reviews, 2015. DOI: 10.1002/14651858.CD004376.pub3.

4. In a 2-year, double-blind RCT of 140 patients with symptomatic knee OA and ultrasound synovitis, intra-articular triamcinolone 40 mg every 12 weeks caused significantly GREATER cartilage volume loss than saline (index-compartment cartilage thickness change -0.21 mm vs -0.10 mm; between-group difference -0.11 mm, 95% CI -0.20 to -0.03) with NO significant difference in pain (-1.2 vs -1.9 on the WOMAC Likert pain subscale).

   McAlindon TE, LaValley MP, Harvey WF, et al. — Effect of Intra-articular Triamcinolone vs Saline on Knee Cartilage Volume and Pain in Patients With Knee Osteoarthritis: A Randomized Clinical Trial.. JAMA, 2017. DOI: 10.1001/jama.2017.5283.

5. The RESTORE trial randomized 288 adults aged 50+ with symptomatic mild-to-moderate medial knee OA to three weekly leukocyte-poor PRP injections or saline placebo. At 12 months, pain change was -2.1 vs -1.8 points (difference -0.4; 95% CI -0.9 to 0.2; P=.17) and medial tibial cartilage volume change was -1.4% vs -1.2% (P=.81). 29 of 31 prespecified secondary outcomes showed no significant between-group difference. The authors concluded the findings 'do not support use of PRP for the management of knee OA.'

   Bennell KL, Paterson KL, Metcalf BR, et al. — Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.. JAMA, 2021. DOI: 10.1001/jama.2021.19415.

6. In a randomized trial of 100 patients with moderate-to-severe knee OA eligible for total knee replacement, TKR followed by 12 weeks of non-surgical care improved the KOOS4 score more than the same non-surgical programme alone (32.5 vs 16.0 points; adjusted mean difference 15.8, 95% CI 10.0 to 21.5) — but produced four times as many serious adverse events (24 vs 6, P=0.005), and 26% of the non-surgical group had chosen surgery within 12 months, meaning roughly three-quarters had not.

   Skou ST, Roos EM, Laursen MB, et al. — A Randomized, Controlled Trial of Total Knee Replacement.. New England Journal of Medicine, 2015. DOI: 10.1056/NEJMoa1505467.

7. In the 68-week STEP 9 trial, 407 participants with obesity (mean BMI 40.3) and moderate knee OA with at least moderate pain were randomized 2:1 to once-weekly semaglutide 2.4 mg or placebo alongside diet and activity counselling. Weight change was -13.7% vs -3.2%, and WOMAC pain improved -41.7 vs -27.5 points (both P<0.001). Gastrointestinal adverse events drove discontinuation in 6.7% vs 3.0%.

   Bliddal H, Bays H, Czernichow S, et al. — Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis.. New England Journal of Medicine, 2024. DOI: 10.1056/NEJMoa2403664.

8. A 2026 systematic review and meta-analysis of eight sham-controlled RCTs (n=627) found genicular nerve ablation (radiofrequency or cryoneurolysis) reduced knee OA pain versus sham at 12 weeks (MD -1.65; 95% CI -2.57 to -0.74) and improved WOMAC function (MD -11.37), with high heterogeneity (I2 83-91%) and no serious adverse events reported. The population studied was patients INELIGIBLE for arthroplasty.

   Pain Medicine authors — Efficacy and safety of genicular nerve ablation techniques for knee osteoarthritis: a systematic review and meta-analysis of sham-controlled randomized trials.. Pain Medicine, 2026. DOI: 10.1093/pm/pnaf140.

9. A prospective longitudinal study of 64 patients with acute medial meniscus posterior root tear managed non-operatively found 76.6% continued non-operative care and only 23.4% converted to surgery (median 6 months). Pain fell from 7.6 to 1.3 on an 11-point scale within 6 months and stayed there — even though structural degeneration on MRI progressed. Symptoms and structure moved in opposite directions.

   Knee Surgery, Sports Traumatology, Arthroscopy authors — Clinical improvement despite structural degeneration after nonoperative treatment of medial meniscus posterior root tear: A prospective longitudinal study.. Knee Surgery, Sports Traumatology, Arthroscopy, 2026. DOI: 10.1002/ksa.70570.

10. A 2026 Cochrane review searching from 2010 to January 2025 found only ONE randomised trial (100 participants, Denmark) comparing knee arthroplasty with non-surgical treatment. Low-certainty evidence indicated TKA may reduce pain at one year by a clinically important margin (MD 17.60, 95% CI 8.25 to 26.95) and may improve function by an amount that might not be clinically important (MD 12.40), with probably no clinically important difference in health-related quality of life.

    Cochrane Musculoskeletal Group — Total and partial knee arthroplasty versus non-surgical interventions of the knee for moderate to severe osteoarthritis.. Cochrane Database of Systematic Reviews, 2026. DOI: 10.1002/14651858.CD015378.pub2.

11. A 2026 network meta-analysis of 21 RCTs (2,254 patients) found both leukocyte-poor and leukocyte-rich PRP significantly improved 6-12 month WOMAC function versus placebo (MD -10.54 and -13.20 respectively) and both were superior to hyaluronic acid, with leukocyte-poor PRP ranked first (P-score 0.96) — a materially more favourable read of PRP than the RESTORE trial, which is why this corpus presents both.

    Journal of Orthopaedic Surgery and Research authors — Leukocyte-rich versus leukocyte-poor platelet-rich plasma and hyaluronic acid for knee osteoarthritis: a systematic review and network meta-analysis.. Journal of Orthopaedic Surgery and Research, 2026. DOI: 10.1186/s13018-026-06689-4.

12. A phase II multicentre RCT randomized 60 knee OA patients to three weekly PRGF injections or 100 million cultured autologous bone marrow mesenchymal stromal cells plus PRGF. No adverse effects were reported. VAS pain improved significantly in the BM-MSC+PRGF arm (5.3 to 3.5, p=0.01) but not in the PRGF-alone arm (5.0 to 4.5, p=0.389) at 12 months — a positive signal at small scale, in an unblinded active-control design.

    Lamo-Espinosa JM, et al. — Phase II multicenter randomized controlled clinical trial on the efficacy of intra-articular injection of autologous bone marrow mesenchymal stem cells with platelet rich plasma for the treatment of knee osteoarthritis.. Journal of Translational Medicine, 2020. DOI: 10.1186/s12967-020-02530-6.

13. FDA states verbatim: 'None of these products have been approved for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain.' The only FDA-approved stem cell products in the United States are blood-forming (hematopoietic progenitor) cells derived from umbilical cord blood, approved only for disorders of blood production. There are currently NO FDA-approved exosome products.

    U.S. Food and Drug Administration — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA (Center for Biologics Evaluation and Research), 2020.